Shares of Verastem Oncology (VSTM) have surged over 40%, reaching $5.17 in premarket trading this Tuesday, in response to a significant regulatory update.
The company's New Drug Application, which seeks accelerated approval for the combination Avutometinib and Defactinib to treat recurrent KRAS mutant low-grade serous ovarian cancer, has received priority review status from the FDA. A decision is anticipated by June 30, 2025.
Low-grade serous ovarian cancer (LGSOC) is a rare ovarian cancer affecting approximately 6,000 to 8,000 women in the United States and about 80,000 globally. This particular form of cancer is highly recurrent and shows limited sensitivity to chemotherapy, with a median survival rate of around ten years. Currently, the standard treatment includes hormone therapy and chemotherapy, but no FDA-approved therapies exist specifically for LGSOC.
The rolling submission for the New Drug Application (NDA) to the FDA began in May of this year and was completed in October, based on data from the phase II registration-directed trial known as RAMP 201. This trial involved patients with recurrent LGSOC, including both KRAS mutant and KRAS wild-type subpopulations.
The RAMP 201 study results were compelling, showing robust overall response rates: 31% overall, 44% in KRAS mutant, and 17% in KRAS wild-type LGSOC patients whose cancer had progressed following chemotherapy and/or treatment with MEK inhibitors and/or bevacizumab. The median progression-free survival (PFS) reported was 12.9 months across all evaluable patients, with 22 months for the KRAS mutant group and 12.8 months for the KRAS wild-type group.
The FDA has indicated that it does not plan to hold an advisory committee meeting to review the NDA.
Should approval be granted, the combination of Avutometinib and Defactinib would mark the first FDA-approved treatment specifically targeting adults with recurrent KRAS mutant LGSOC.
Previously, when we highlighted VSTM on October 17, 2024, it was trading at $3.18. As of this morning's premarket trading, the stock has climbed nearly 41% to $5.17.
The material has been provided by InstaForex Company - www.instaforex.com
The company's New Drug Application, which seeks accelerated approval for the combination Avutometinib and Defactinib to treat recurrent KRAS mutant low-grade serous ovarian cancer, has received priority review status from the FDA. A decision is anticipated by June 30, 2025.
Low-grade serous ovarian cancer (LGSOC) is a rare ovarian cancer affecting approximately 6,000 to 8,000 women in the United States and about 80,000 globally. This particular form of cancer is highly recurrent and shows limited sensitivity to chemotherapy, with a median survival rate of around ten years. Currently, the standard treatment includes hormone therapy and chemotherapy, but no FDA-approved therapies exist specifically for LGSOC.
The rolling submission for the New Drug Application (NDA) to the FDA began in May of this year and was completed in October, based on data from the phase II registration-directed trial known as RAMP 201. This trial involved patients with recurrent LGSOC, including both KRAS mutant and KRAS wild-type subpopulations.
The RAMP 201 study results were compelling, showing robust overall response rates: 31% overall, 44% in KRAS mutant, and 17% in KRAS wild-type LGSOC patients whose cancer had progressed following chemotherapy and/or treatment with MEK inhibitors and/or bevacizumab. The median progression-free survival (PFS) reported was 12.9 months across all evaluable patients, with 22 months for the KRAS mutant group and 12.8 months for the KRAS wild-type group.
The FDA has indicated that it does not plan to hold an advisory committee meeting to review the NDA.
Should approval be granted, the combination of Avutometinib and Defactinib would mark the first FDA-approved treatment specifically targeting adults with recurrent KRAS mutant LGSOC.
Previously, when we highlighted VSTM on October 17, 2024, it was trading at $3.18. As of this morning's premarket trading, the stock has climbed nearly 41% to $5.17.
The material has been provided by InstaForex Company - www.instaforex.com